MAPK Signaling
Activated MAPKs transduce the phosphorylation and activation of MAPK-activated protein kinases (MAPKAPKs), e.g. RSK, MSK, or MNK family, and MK2/3/5. There are three main MAPK families, signal-regulated kinase 1 and 2 (Erk1/2 or p44/42), the c-Jun N-terminal kinases 1-3 (JNK1-3)/ stress activated protein kinases (SAPK1A, 1B, 1C), the p38 isoforms (p38α, β, γ, and δ). ERK signaling is involved in cell division, migration and survival. p38 MAPK and JNK/SAPK pathways are activated by cellular stress. The p38 MAPK pathway regulates cell motility, transcription, and chromatin remodeling. JNK/SAPK signaling affects apoptosis and inflammation. Dysregulation of MAPK pathway results in tumorgenesis and other pathological conditions.
-
A3347 Dabrafenib Mesylate (GSK-2118436)Target: RafSummary: Inhibitor of BRAF(V600) mutants
-
A3887 Trametinib DMSO solvate1 CitationTarget: MEKSummary: Allosteric MEK1/MEK2 kinase inhibitor
-
A3943 XMD8-92Target: ERKSummary: BMK1/ERK5 inhibitor
-
B1267 RefametinibTarget: MEKSummary: MEK 1/ MEK 2 inhibitor
-
B1135 GDC-0623Target: MEKSummary: MEK1 inhibitor, potent and ATP-uncompetitive
-
A8374 AZD8330Target: MEKSummary: MEK 1/2 inhibitor
-
A3004 Vemurafenib (PLX4032, RG7204)9 CitationTarget: RafSummary: BRAF kinase inhibitor
-
A3009 Sorafenib2 CitationTarget: Raf|VEGFRSummary: Raf kinases and tyrosine kinases inhibitor
-
A3016 PLX-47201 CitationTarget: RafSummary: BRAF kinase inhibitor
-
A3018 Trametinib (GSK1120212)7 CitationTarget: MEKSummary: MEK1 and MEK2 inhibitor, potent and selective